Overview of Advanced RCC and Diagnosis

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained benefit at 5 years post surgery.